Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,253) Arrow Down
Filter Results: (1,253) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,253)
    • People  (5)
    • News  (175)
    • Research  (927)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (758)

Show Results For

  • All HBS Web  (1,253)
    • People  (5)
    • News  (175)
    • Research  (927)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (758)
← Page 11 of 1,253 Results →
  • October 2019
  • Supplement

Impax Laboratories: Executing Accretive Acquisitions (B)

By: Benjamin C. Esty and Daniel Fisher
Explores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016. View Details
Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
Citation
Purchase
Related
Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (B)." Harvard Business School Supplement 220-031, October 2019.
  • May 2005 (Revised April 2010)
  • Case

GlaxoSmithKline: Reorganizing Drug Discovery (A)

By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)
  • 28 Sep 2015
  • News

Healthcare Inequality

  • May 2001 (Revised August 2001)
  • Case

e-Business@Novartis

By: Andrew P. McAfee, Carin-Isabel Knoop and Cate Reavis
Describes a leading pharmaceutical company's approach to developing e-business capabilities throughout the organization. Highlights the company's decision to approach e-business on a more centralized manner. View Details
Keywords: Strategy; Online Technology; Pharmaceutical Industry
Citation
Educators
Purchase
Related
McAfee, Andrew P., Carin-Isabel Knoop, and Cate Reavis. "e-Business@Novartis." Harvard Business School Case 601-057, May 2001. (Revised August 2001.)
  • September 2002 (Revised August 2014)
  • Case

Cardinal Health (A): The Medicine Shoppe Acquisition

By: Regina E. Herzlinger, Miguel Abecasis and Brenda Cheng
Robert Walter, the founder and CEO of Cardinal Health, a pharmaceutical distributor, is contemplating the purchase of Medicine Shoppe, a chain of apothecaries. The purchase might be construed as competition against his own drugstore customers. But one of its many... View Details
Keywords: Mergers and Acquisitions; Business Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Herzlinger, Regina E., Miguel Abecasis, and Brenda Cheng. "Cardinal Health (A): The Medicine Shoppe Acquisition." Harvard Business School Case 303-043, September 2002. (Revised August 2014.)
  • 05 Feb 2019
  • Video

Health Care Webinar

  • May 2004 (Revised June 2004)
  • Case

Brief Biographical Note on P. Roy Vagelos

By: Nitin Nohria and Bridget Gurtler
Provides background biographical information on P. Roy Vagelos, chief executive officer of Merck Pharmaceuticals. Teaching Purpose: To chart the development of a leader in the pharmaceutical industry. View Details
Keywords: Biography; Teaching; Leadership Development; Mission and Purpose; Personal Development and Career; Ethics; Pharmaceutical Industry
Citation
Find at Harvard
Related
Nohria, Nitin, and Bridget Gurtler. "Brief Biographical Note on P. Roy Vagelos." Harvard Business School Case 404-132, May 2004. (Revised June 2004.)
  • January 2007 (Revised April 2011)
  • Case

Farmacias Similares: Private and Public Health Care for the Base of the Pyramid in Mexico

By: Michael Chu and Regina Garcia-Cuellar
Farmacias Similares, serving Mexico's low-income sector, grew to $600 million sales and 3,400 drugstores while deep reforms to help the poor swept the public health system. Adjacent to each store, for $2 per visit, medical clinics provided access to doctors for 2.3... View Details
Keywords: Private Sector; Public Sector; Health Care and Treatment; Growth and Development Strategy; Poverty; Pharmaceutical Industry; Pharmaceutical Industry; Mexico
Citation
Educators
Purchase
Related
Chu, Michael, and Regina Garcia-Cuellar. "Farmacias Similares: Private and Public Health Care for the Base of the Pyramid in Mexico." Harvard Business School Case 307-092, January 2007. (Revised April 2011.)
  • November 2010 (Revised December 2010)
  • Background Note

HR 3509

By: David F. Hawkins
HR 3509 ("2010 Health Reform Bill") imposition of a fee in pharmaceutical sales and an excise tax on medical device sales raises accounting issues. View Details
Keywords: Accounting; Governing Rules, Regulations, and Reforms; Government Legislation; Taxation; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Find at Harvard
Related
Hawkins, David F. "HR 3509." Harvard Business School Background Note 111-056, November 2010. (Revised December 2010.)
  • February 2001
  • Background Note

National Innovation Systems and Comparative Industry Evolution

Discusses U.S. and Japanese innovation systems. Illustrates these with comparative studies of computer and pharmaceutical industries. Probes effects of labor, capital, and customer market institutions on these sectors in the United States and Japan. View Details
Keywords: Industry Growth; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; Japan; United States
Citation
Educators
Purchase
Related
Chesbrough, Henry W., and Gillian Morris. "National Innovation Systems and Comparative Industry Evolution." Harvard Business School Background Note 601-049, February 2001.
  • December 1999 (Revised August 2001)
  • Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Pharmaceutical Industry; Pharmaceutical Industry; Cambridge
Citation
Educators
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (A)." Harvard Business School Case 600-038, December 1999. (Revised August 2001.)
  • August 2009 (Revised August 2012)
  • Case

Cabot Pharmaceuticals, Inc.

By: Frank V. Cespedes and John T. Gourville
Traces the 12-year career of a pharmaceutical salesperson, Bob Marsh, from recruitment to termination. Marsh has had an uneven career with Cabot Pharmaceuticals and eventually is asked to resign. Following his termination, a number of Marsh's former customers complain... View Details
Keywords: Customer Relationship Management; Employees; Resignation and Termination; Performance Evaluation; Salesforce Management; Alignment; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Cespedes, Frank V., and John T. Gourville. "Cabot Pharmaceuticals, Inc." Harvard Business School Case 510-030, August 2009. (Revised August 2012.)
  • 15 Sep 2016
  • News

Price of pharma innovation: Pro

  • 20 Mar 2015
  • News

Big Pharma Needs to Get Busy in the Lab

  • 01 Oct 2011
  • News

Resistance Is Futile

  • 09 Nov 2011
  • News

Resistance Is Futile

  • December 2007 (Revised May 2009)
  • Case

Can PACIV (Puerto Rico) Serve European Customers?

Jorge Rodriguez-Gonzalez, PACIV's (Puerto Rico) founding CEO, is considering expanding PACIV's pharmaceutical manufacturing compliance services company to the U.K. and Europe. He has to decide whether to hire Wayne Snelgrove and how to define the scope of his... View Details
Keywords: Customer Focus and Relationships; Entrepreneurship; Cross-Cultural and Cross-Border Issues; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Europe; United Kingdom; Puerto Rico
Citation
Educators
Purchase
Related
Isenberg, Daniel J. "Can PACIV (Puerto Rico) Serve European Customers?" Harvard Business School Case 808-099, December 2007. (Revised May 2009.)
  • November 2008 (Revised July 2009)
  • Background Note

A Managerial Perspective on Clinical Trials

By: Arthur A. Daemmrich
This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Safety; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Daemmrich, Arthur A. "A Managerial Perspective on Clinical Trials." Harvard Business School Background Note 709-033, November 2008. (Revised July 2009.)
  • December 1996 (Revised June 2003)
  • Case

Cynthia Hogan and the Birth of Novartis

By: Rosabeth M. Kanter
An American woman heads an integration office for merger transition activities between two giant Swiss pharmaceutical companies. She needed to develop an implementation plan to shape the new global powerhouse. View Details
Keywords: Mergers and Acquisitions; Global Strategy; Organizational Design; Strategic Planning; Pharmaceutical Industry; Switzerland; United States
Citation
Educators
Related
Kanter, Rosabeth M. "Cynthia Hogan and the Birth of Novartis." Harvard Business School Case 897-126, December 1996. (Revised June 2003.)
  • September 1990 (Revised January 1992)
  • Case

Eli Lilly and Co. (A): Globalization

By: Michael Y. Yoshino
Examines the changes taking place in Eli Lilly in response to the globalization of the pharmaceuticals industry. Identifies the steps taken by management, problems currently faced, and challenges for the future. Allows examination of the process of implementing a... View Details
Keywords: Change; Globalization; Global Strategy; Business or Company Management; Problems and Challenges; Perspective; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Yoshino, Michael Y. "Eli Lilly and Co. (A): Globalization." Harvard Business School Case 391-032, September 1990. (Revised January 1992.)
  • ←
  • 11
  • 12
  • …
  • 62
  • 63
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.